Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis - Annals of Hematology

Patients

15

Female, n (%)

10

Male, n (%)

5

Age, median (range)*

49 (5–70)

Diagnosis

AML, n (%)

7 (47)

ALL, n (%)

2 (13)

MPN (%)

3 (15)

Others, n (%)

3 (15)

Donor type

HLA-matched unrelated, n (%)

7 (47)

HLA-mismatched unrelated, n (%)

1 (7)

HLA-matched related, n (%)

6 (40)

HLA-mismatched related, n (%)

0

Haploidentical related, n (%)

1 (7)

Sex mismatch: female to male

Yes, n (%)

1 (7)

No, n (%)

14 (93)

Stem cell source

Peripheral blood stem cells, n (%)

14 (93)

Bone marrow, n (%)

1 (7)

GvHD prophylaxis

ATG/CsA/MTX, n (%)

3 (20)

CsA/MTX, n (%)

5 (33)

CsA/MMF, n (%)

1 (7)

Other

6 (40)

History of aGvHD

Grades 0–I, n (%)

4 (27)

Grades II–IV, n (%)

11 (73)

Characteristics

Value

Onset of cGvHD after allo-SCT, median days (range)

256 (76–597)

Time point of abatacept treatment after allo-SCT, median days, (range)

1848 (432–7953)

Time point of abatacept treatment after cGvHD onset, median days, (range)

1592 (133–7864)

Age at abatacept initiation, median (range)

49 (5–70)

Number of abatacept doses, median (range)

7.1 (1–20)

cGvHD, n (%)

Mild

1 (7)

Moderate

0

Severe

non-NIH defined (AIHA)

13 (87)

1 (7)

Steroid response of cGvHD

Steroid resistance

5 (33)

Steroid dependence

10 (67)

Number of organ involvement of cGvHD, n (%)

One

1 (7)

Two

1 (7)

Three

5 (33)

Four or more

8 (53)

Type of cGvHD organ involvement, n (%)

Skin

11 (73)

Oral

10 (67)

Eyes

10 (67)

Liver

2 (13)

Gut

4 (27)

Lung

11 (73)

Musculoskeletal

7 (47)

Genital

2 (13)

AIHA

1 (7)

ISM at the beginning of abatacept, n (%)

No ISM

0

One ISM

5 (33)

Two ISM

8 (53)

Three or more ISM

2 (13)

Number of prior therapies before abatacept, n (%)

One

2 (13)

Two

2 13)

Three

1 (7)

Four or more prior therapies

10 (67)

New ISM within 3 months before abatacept, n (%)

Yes

3 (20)

No

12 (80)